入院前口服糖皮质激素与脓毒症危重成人急性呼吸窘迫综合征风险降低相关
该回顾性观察研究纳入某学术医疗中心内科、外科、创伤及心血管ICU的1080例脓毒症危重患者,比较入院前是否口服糖皮质激素与入住ICU后96小时内急性呼吸窘迫综合征发生的关系。未校正的急性呼吸窘迫综合征发生率在口服激素组为35%、未口服组为42%(p=0.107);多因素分析校正预设混杂因素后,入院前口服糖皮质激素与急性呼吸窘迫综合征发生率降低独立相关(OR 0.53;95%CI 0.33-0.84;p=0.008),多项敏感性分析结果一致。165例口服激素患者的中位日剂量为泼尼松等效10 mg(四分位距5-30 mg),较高剂量与更低急性呼吸窘迫综合征发生率相关(30 mg相比5 mg的OR 0.53;95%CI 0.32-0.86)。入院前口服糖皮质激素与院内死亡率(OR 1.41;95%CI 0.87-2.28;p=0.164)、ICU住院时间(OR 0.90;95%CI 0.63-1.30;p=0.585)及无呼吸机天数(OR 1.06;95%CI 0.71-1.57;p=0.783)无关。
要点
- 在脓毒症ICU患者中,入院前口服糖皮质激素与入住ICU后96小时内急性呼吸窘迫综合征发生率降低独立相关(OR 0.53;95%CI 0.33-0.84;p=0.008)。
- 未校正分析中,口服激素组急性呼吸窘迫综合征发生率为35%,未口服组为42%(p=0.107)。
- 165例口服激素患者的中位日剂量为泼尼松等效10 mg(四分位距5-30 mg);30 mg相比5 mg的OR为0.53(95%CI 0.32-0.86)。
- 入院前口服糖皮质激素与院内死亡率(OR 1.41;95%CI 0.87-2.28;p=0.164)、ICU住院时间(OR 0.90;95%CI 0.63-1.30;p=0.585)及无呼吸机天数(OR 1.06;95%CI 0.71-1.57;p=0.783)无关。
适用人群与场景
- 某学术医疗中心内科、外科、创伤及心血管ICU的1080例脓毒症危重患者。
研究设计与关键结果
- 回顾性观察研究,纳入1080例脓毒症危重患者,比较入院前口服糖皮质激素者与未使用者。
- 未校正的急性呼吸窘迫综合征发生率在口服激素组为35%,未口服组为42%(p=0.107)。
- 多因素分析校正预设混杂因素后,入院前口服糖皮质激素与入住ICU后96小时内急性呼吸窘迫综合征发生率降低独立相关(OR 0.53;95%CI 0.33-0.84;p=0.008),多项敏感性分析结果一致。
- 165例口服激素患者的中位日剂量为泼尼松等效10 mg(四分位距5-30 mg);较高剂量与更低急性呼吸窘迫综合征发生率相关(30 mg相比5 mg的OR 0.53;95%CI 0.32-0.86)。
- 入院前口服糖皮质激素与院内死亡率(OR 1.41;95%CI 0.87-2.28;p=0.164)、ICU住院时间(OR 0.90;95%CI 0.63-1.30;p=0.585)及无呼吸机天数(OR 1.06;95%CI 0.71-1.57;p=0.783)无关。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒症ICU患者中,入院前口服糖皮质激素与早期急性呼吸窘迫综合征发生率降低独立相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the association between preadmission oral corticosteroid receipt and the development of acute respiratory distress syndrome in critically ill patients with sepsis.
DESIGN: Retrospective observational study.
SETTING: Medical, surgical, trauma, and cardiovascular ICUs of an academic medical center.
PATIENTS: A total of 1,080 critically ill patients with sepsis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The unadjusted occurrence rate of acute respiratory distress syndrome within 96 hours of ICU admission was 35% among patients who had received oral corticosteroids compared with 42% among those who had not (p = 0.107). In a multivariable analysis controlling for prespecified confounders, preadmission oral corticosteroids were associated with a lower incidence of acute respiratory distress syndrome in the 96 hours after ICU admission (odds ratio, 0.53; 95% CI, 0.33-0.84; p = 0.008), a finding that persisted in multiple sensitivity analyses. The median daily dose of oral corticosteroids among the 165 patients receiving oral corticosteroids, in prednisone equivalents, was 10 mg (interquartile range, 5-30 mg). Higher doses of preadmission oral corticosteroids were associated with a lower incidence of acute respiratory distress syndrome (odds ratio for 30 mg of prednisone compared with 5 mg 0.53; 95% CI, 0.32-0.86). In multivariable analyses, preadmission oral corticosteroids were not associated with in-hospital mortality (odds ratio, 1.41; 95% CI, 0.87-2.28; p = 0.164), ICU length of stay (odds ratio, 0.90; 95% CI, 0.63-1.30; p = 0.585), or ventilator-free days (odds ratio, 1.06; 95% CI, 0.71-1.57; p = 0.783).
CONCLUSIONS: Among ICU patients with sepsis, preadmission oral corticosteroids were independently associated with a lower incidence of early acute respiratory distress syndrome.
参考来源
- McKown AC, McGuinn EM, Ware LB, et al. Preadmission Oral Corticosteroids Are Associated With Reduced Risk of Acute Respiratory Distress Syndrome in Critically Ill Adults With Sepsis. Crit Care Med. 2017. PMID: 28257336. doi:10.1097/CCM.0000000000002286
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。